What is the clinical evidence from this study?

Study design: Other. Intervention: Goat anti-rat hepatic lipase serum vs. Control rats. Primary outcome: Apolipoprotein B-48 as a percentage of total apolipoprotein B in the LDL fraction.

What does this research mean for the field?

Inhibition of hepatic lipase in rats leads to marked enrichment of apolipoprotein B-48 in the low-density lipoprotein fraction and demonstrates a direct role for hepatic lipase in chylomicron catabolism. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

June 1, 1986Biochimica et Biophysica Acta (BBA) - Lipids and Lipid MetabolismOpen Access

Enrichment of apolipoprotein B-48 in the LDL density class following in vivo inhibition of hepatic lipase

View Full Paper

Ask AI

Bookmark

Key result

Hepatic lipase inhibition in rats increases LDL apolipoprotein B-48 enrichment ~5-fold.

Population

Rats (fasting and fat-loaded models)

Comparison

Goat anti-rat hepatic lipase serum injection vs Control rats

Design

Preclinical

Follow-up

6 hours post-inhibition (for fat-loaded rats)

Authors

BDBruce P. Daggy ABAndré Bensadoun

Discussion

Member takes

Overview

Hypothesis-generating in rats; leaves open hepatic lipase as a therapeutic target pending human validation.

Structured PICO

Population

Rats (fasting and fat-loaded) used to explore the in vivo function of hepatic lipase.

Intervention

Goat anti-rat hepatic lipase serum injection (in vivo inhibition of hepatic lipase)

Comparator

Control rats

Outcome

Lipoprotein composition and apolipoprotein B-48 enrichment in LDL and HDL fractionssurrogate

Main Result

Absolute Event Rate: 62% vs 12%

In vivo inhibition of hepatic lipase in rats leads to enrichment of apolipoprotein B-48 in the LDL fraction, supporting its role as a phospholipase and in chylomicron catabolism.

Cite This Study

Daggy et al. (1986) studied this question. Goat anti-rat hepatic lipase serum vs. Control rats was evaluated on Apolipoprotein B-48 as a percentage of total apolipoprotein B in the LDL fraction. Inhibition of hepatic lipase in rats significantly enriched the LDL fraction with apolipoprotein B-48 (62% of total apolipoprotein B vs. 12% in controls).

synapsesocial.com/papers/6aa6b1e25becb0bc28eede8e https://doi.org/10.1016/0005-2760(86)90302-4

View Full Paper

Ask AI

Bookmark

June 1, 1986Biochimica et Biophysica Acta (BBA) - Lipids and Lipid MetabolismOpen Access

Enrichment of apolipoprotein B-48 in the LDL density class following in vivo inhibition of hepatic lipase

View Full Paper

Ask AI

Bookmark

Key result

Hepatic lipase inhibition in rats increases LDL apolipoprotein B-48 enrichment ~5-fold.

Population

Rats (fasting and fat-loaded models)

Comparison

Goat anti-rat hepatic lipase serum injection vs Control rats

Design

Preclinical

Follow-up

6 hours post-inhibition (for fat-loaded rats)

Authors

BDBruce P. Daggy ABAndré Bensadoun

Discussion

Member takes

Overview

Hypothesis-generating in rats; leaves open hepatic lipase as a therapeutic target pending human validation.

Structured PICO

Population

Rats (fasting and fat-loaded) used to explore the in vivo function of hepatic lipase.

Intervention

Goat anti-rat hepatic lipase serum injection (in vivo inhibition of hepatic lipase)

Comparator

Control rats

Outcome

Lipoprotein composition and apolipoprotein B-48 enrichment in LDL and HDL fractionssurrogate

Main Result

Absolute Event Rate: 62% vs 12%

In vivo inhibition of hepatic lipase in rats leads to enrichment of apolipoprotein B-48 in the LDL fraction, supporting its role as a phospholipase and in chylomicron catabolism.

Cite This Study

synapsesocial.com/papers/6aa6b1e25becb0bc28eede8e https://doi.org/10.1016/0005-2760(86)90302-4

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark